CYP2D6 and breast carcinoma: On the contrary, the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommend against using CYP2D6 genotype to guide the selection of adjuvant endocrine therapy [20–22].